Immix Biopharma
clinical data month in late stage sarcoma well tolerated oat immix | Immix Biopharma
Company
Deck Type
Sector
Industry
Deck date
January 2024
Slide
54 of 64
Similar slides by Immix Biopharma
See diffirences between slides (animation)
Investor Presentation
March 2024
clinical data month in late stage sarcoma well tolerated immix months immix | Immix Biopharma
Investor Presentation
December 2023
clinical data month in late stage sarcoma well tolerated oat immix | Immix Biopharma
Investor Presentation
November 2023
clinical data month in late stage sarcoma well tolerated oat immix | Immix Biopharma
Investor Presentation
November 2023
clinical data month in late stage sarcoma well tolerated oat immix | Immix Biopharma
Related slides by other companies
Aeglea BioTherapeutics
Investor Presentation
May 2023
program overview | Aeglea BioTherapeutics
Mainz Biomed NV
Investor Presentation
June 2023
next generation clinical validation and trials late | Mainz Biomed NV
Coupang
Investor Presentation
October 2023
progression towards free cash flow positive | Coupang
Ocuphire Pharma
Investor Day
January 2022
submission targeted in late | Ocuphire Pharma
Other recent decks by Immix Biopharma
See all presentations (11 decks)
Investor Presentation
March 2024
Investor Presentation
December 2023
Investor Presentation
November 2023
Investor Presentation
November 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights